| Multiple Sclerosis |
1 |
1 |
| Lipids Management |
0 |
0.6 |
| Pandemic |
0 |
0.55 |
| Cardiovascular Risk Management |
0 |
0.4 |
| COVID-19 |
0 |
0.4 |
| Disability |
0 |
0.36 |
| Hospital |
0 |
0.36 |
| Biologic Therapy |
0 |
0.2 |
| Healthcare and Medical Technology |
0 |
0.2 |
| Biomarker |
0 |
0.18 |
| Brain |
0 |
0.18 |
| Cardiovascular disease |
0 |
0.18 |
| Clinical Research |
0 |
0.18 |
| Magnetic Resonance Imaging |
0 |
0.18 |
| Monoclonal Antibody |
0 |
0.18 |
| Multiple Sclerosis Progression |
0 |
0.18 |
| Multiple Sclerosis Treatment |
0 |
0.18 |
| Neurosurgery |
0 |
0.18 |
| Pedal |
0 |
0.18 |
| Rhabdomyolysis |
0 |
0.18 |
| Secondary Progressive Multiple Sclerosis |
0 |
0.18 |
| Statins |
0 |
0.18 |